Cerebrolysin

Status Approved as a prescription drug in Austria, Russia, China and other jurisdictions; not approved by the FDA or EMABest evidence E3Sources checked 2026-09-18

Cerebrolysin is a manufactured mixture of peptide fragments and amino acids from enzymatically digested porcine brain tissue, not a single peptide. It has real Western randomized placebo-controlled trials in stroke, Alzheimer’s disease and subarachnoid hemorrhage, with mixed results, and no FDA or EMA approval.

What it is

Cerebrolysin is a manufactured drug, not a single defined peptide. It is produced by standardized enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptide fragments (about 25% of the preparation by the manufacturer’s account) and free amino acids (about 75%). It is manufactured by EVER Neuro Pharma (Austria) and is approved as a prescription drug in Austria, Russia, China and several other countries as a “nootropic” and neuroprotective agent. It has never been approved by the FDA or the EMA, and it has no United States prescribing information.

Because it is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic: proposed effects include neurotrophic-factor-like activity, reduced excitotoxicity, and anti-inflammatory action, none of which has been pinned to a single active component in the sources reviewed for this entry.

The human trial record

Cerebrolysin has more Western, randomized, double-blind, placebo-controlled human trials behind it than most compounds on this site, and the results across them do not point in one direction.

The Cerebrolysin and Recovery After Stroke (CARS) trial, a multicenter randomized double-blind placebo-controlled study, gave stroke patients 30 mL/day of Cerebrolysin by daily infusion for 21 days, starting 24 to 72 hours after stroke onset, alongside standardized rehabilitation. It reported a large effect favoring Cerebrolysin on upper-extremity motor function (Action Research Arm Test) at day 90, and the authors themselves described the study as exploratory with a relatively small sample size, calling for confirmation in a larger trial.

A separate randomized, double-blind, placebo-controlled pilot trial in 50 patients with aneurysmal subarachnoid hemorrhage, using the same 30 mL/day dose for 14 days, found no significant difference between Cerebrolysin and placebo on six-month functional outcome, cognitive performance, or the rate of delayed cerebral ischemia. It was safe and well tolerated, but neutral on efficacy.

A 2015 meta-analysis pooling six randomized, double-blind, placebo-controlled trials of 30 mL/day of Cerebrolysin in mild-to-moderate Alzheimer’s disease reported a statistically significant benefit on cognitive function at 4 weeks and on global clinical change at both 4 weeks and 6 months, with a safety profile comparable to placebo.

A completed Phase 2 trial in Down syndrome and ongoing motor-recovery trials after stroke round out a body of research that keeps returning to this compound for different indications, without any single result being decisive.

What is not known

Which component of this multi-molecule mixture, if any, is responsible for the effects reported in some trials and absent in others. A defined single active ingredient has not been isolated in the sources reviewed for this entry.

Why the subarachnoid hemorrhage trial and the stroke motor-recovery trial reached different conclusions at the same 30 mL/day dose. Population, timing after injury and outcome measure all differed between them, and no synthesis reconciling the results was located.

Whether the results generalise to indications outside stroke, Alzheimer’s disease and Down syndrome, the three areas with published randomized trials.

What is not known

Which component of this multi-molecule mixture, if any, drives the effects reported in some trials. No single active ingredient has been isolated in the sources reviewed for this entry.

Why trials in different acute brain injury populations, at the same dose, reached different conclusions.

Whether results in stroke, Alzheimer’s disease and Down syndrome generalise to other uses this compound is marketed for.

Doses used in published research

No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.

Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.

Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported use	Route	Amount reported	Frequency	Reported length
Cognitive/nootropic use, general	Intramuscular or subcutaneous	1 to 5 mL per dose (from 5 mL or 10 mL ampoules)	Once daily, often cycled in courses	10 to 20 day courses

Cerebrolysin is manufactured and sold as 1, 5, 10, 20 and 30 mL ampoules for clinical IM or IV use, and circulating self-use material generally describes 1 to 5 mL by intramuscular or subcutaneous injection, once daily. The published trials used 30 mL per day by IV infusion, which would take 6 to 30 of those same ampoules to match. A self-administered intramuscular dose in the low single-digit milliliters is a fraction of the volume, and by a different route, than what any cited trial actually tested.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.